相关实验视频
Updated: May 6, 2026
04:27
Intratracheal Instillation of Stem Cells in Term Neonatal Rats
Published on: May 4, 2020
5.4K
甲基普雷尼索隆用于婴儿心脏手术:随机对照试验的亚群分析
Sudeep D Sunthankar1, Kevin D Hill2, Jeffrey P Jacobs3
1Thomas P. Graham Jr. Division of Pediatric Cardiology and Center for Pediatric Precision Medicine, Department of Pediatrics, Monroe Carell Jr. Children's Hospital at Vanderbilt and Vanderbilt University Medical Center, Nashville, TN.
Critical care medicine
|May 21, 2025
概括
在婴儿心脏手术中,预防性手术内甲基prednisolone 显示了诸如减少皮的使用等益处,但也显示了诸如早产婴儿血栓形成增加和血糖升高等风险. 某些婴儿群体可能会在没有显著伤害的情况下受益.
科学领域:
- 心脏病学 心脏病学
- 儿科手术 儿科手术
- 药理学 药理学是指药理学的学科.
背景情况:
- 婴儿心脏手术带有系统性炎症和并发症的风险.
- 预防性皮质类固醇用于减轻这些风险.
- 在STRESS试验中,研究了甲基prednisolone的疗效和安全性.
研究的目的:
- 在接受心脏手术的婴儿的特定亚群中评估预防性手术内甲基普雷迪尼索隆的益处和危害.
- 确定可能从这种干预中受益或受到损害的子组.
主要方法:
- 来自STRESS试验的亚种群分析,这是一项双盲,随机,安慰剂控制的研究.
- 通过心肺旁路进行心脏手术的婴儿 (<1岁) 根据STAT类别,年龄,妊娠年龄和CSD进行了分层.
- 在心肺旁路过程中使用甲基prednisolone (30 mg/kg) 或安慰剂.
主要成果:
- 甲基普雷尼索隆减少了新生儿,STAT类别1-5的婴儿和没有CSD的婴儿的手术后皮激素的使用.
- 在接受甲基prednisolone的新生儿和满期婴儿中观察到较低的血栓形成率.
- 副作用包括早产婴儿血栓形成的增加,新生儿和STAT 1-3组的AKI增加,以及各子组血糖和胰岛素峰值的升高.
结论:
- 预防性甲基普雷迪尼索隆证明了好处 (降低皮,没有增加感染) 和危害 (增加葡萄糖,潜在的AKI风险).
- 特定的子群体可能会从其使用中受益,但需要仔细考虑风险.
- 进一步的研究可能会完善患者选择以获得最佳的结果.
相关概念视频
01:29Drug Dosing: Infants and Children
1.0K
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
558
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
558
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
414
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
414